TITLE

Dabigatran Leading Race to Replace Warfarin

PUB. DATE
November 2010
SOURCE
Travel Medicine Advisor;Nov2010 Supplement, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the recommendation for approval of dabigatran, from Boehringer Ingelheim, by the Food and Drug Administration in the U.S. It mentions that the said drug contains proton pump inhibitors (PPIs), the same components found in treatments for cardiovascular diseases. Dabigatran is considered an effective replacement for warfarin.
ACCESSION #
54627506

 

Related Articles

  • FDA approves Nexium.  // Medical Marketing & Media;Mar2001, Vol. 36 Issue 3, p6 

    Reports on the approval of Food and Drug Administration on the labeling of Nexium, a proton pump inhibitor in the U.S. Efficacy in treating heartburn; Price offering of the drug; Budget allocated for the promotion of Nexium.

  • FDA decides against fracture warning for OTC PPIs.  // Pharmacy Today;May2011, Vol. 17 Issue 5, p6 

    The article reports on the decision of Food and Drug Administration (FDA) concerning the osteoporosis and fracture warning on over-the-counter (OTC) proton pump inhibitor (PPIs) drugs in the U.S.

  • FDA Actions.  // Clinical Oncology Alert;May2010 Supplement, p2 

    The article discusses the actions of the U.S. Food and Drug Administration (FDA) on drugs used for the treatment of type 2 diabetes, such as the antiplatelet drug clopidogrel, the proton pump inhibitor dexlansoprazole from Dexilant, and the generic version of Boeringer Ingelheim's tamsulosin.

  • New PPI approved. Maudlin, Robert K. // Modern Medicine;Dec99, Vol. 67 Issue 12, p53 

    Reports on the approval of proton pump inhibitor rabeprazole sodium by the United States Food and Drug Administration. Medical significance of rabeprazole; Dosage for healing ulcerative gastroesophageal reflux disease; Results of clinical trials of the drug.

  • PPI Product Safety Alert.  // Monthly Prescribing Reference;Mar2012, Vol. 28 Issue 3, pA-20 

    The article offers information on the alert issued by the U.S. Food and Drug Administration against the use of proton pump inhibitors (PPIs) as it can increase the risk of Clostridium difficile-associated diarrhea (CDAD).

  • MED WATCH: FDA Warns About Link Between PPI Use and Severe Diarrhea.  // American Family Physician;3/15/2012, Vol. 85 Issue 6, p554 

    The article highlights a drug safety warning issued by the U.S. Food and Drug Administration (FDA) which suggests that use of proton pump inhibitors (PPI) may increase the risk of Clostridium difficile-associated diarrhea.

  • US FDA revises labelling for PPIs.  // Reactions Weekly;6/5/2010, Issue 1304, p2 

    The article reports on the revisions made by the U.S. Food and Drug Administration to the labels for all prescription and over-the-counter (OTC) proton pump inhibitors (PPI) to include new safety information about the possibly increased risk of hip, wrist and spine fractures linked with use of...

  • Prilosec switch could impact OTC. Alexander, Antoinette // Drug Store News;7/22/2002, Vol. 24 Issue 9, p10 

    Deals with the possibility that AstraZeneca's indigestion remedy Prilosec will be sold without a prescription after a panel of U.S. Food and Drug Administration advisory committees recommended the switch in June 2002. Impact on prescription sales of other proton pump inhibitors; Advantage of...

  • PPIs Could have Long-Term Risks.  // Pharmaceutical Representative;Jul2010, Vol. 40 Issue 7, p11 

    The article reports that the U.S. Food and Drug Administration warned consumers and health care professionals about a possible increased risk of fractures of the hip, wrist, and spine with high doses or long-term use of a class proton pump inhibitors.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics